Why Hims & Hers Health, Inc. (HIMS) Skyrocketed On Tuesday

We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other Tuesday’s best-performing stocks.

The stock market ended the trading session in the red on Tuesday, with all major indices giving up earlier gains, as investors sold off positions while waiting for the results of the Federal Reserve’s policy decision, while digesting President Donald Trump’s new tariff policies.

Among all the major indices, the Dow Jones fell the heaviest, down 0.95 percent. The tech-heavy Nasdaq followed with a 0.87-percent decline, while the S&P 500 finished with a 0.77-percent drop.

Beyond the major indices, 10 firms stood out with strong gains amid a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Tuesday’s 10 best-performing stocks and detail the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.

A nurse in a telehealth platform talking with a patient on video call for consultation.

Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers rallied for a fourth consecutive day on Tuesday, jumping 18.12 percent to end at $49.47 each, as investor sentiment was fueled by its impressive earnings performance in the first quarter of the year and announcements that more collaborations are expected.

In its financial statement, Hims & Hers Health, Inc. (NYSE:HIMS) said net income expanded by 346 percent to $49.5 million from the $11.1 million registered in the same period last year. Revenues soared by 111 percent to $586 million from $278.2 million year-on-year.

According to the company, the strong performance underpinned its updated 2025 guidance, with full-year revenues expected to settle between $2.3 billion and $2.4 billion, and between $530 million and $550 million for the second quarter.

In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy.

With the partnership, Americans can now access NovoCare Pharmacy directly through its platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, including access to 24/7 care, ongoing clinical support, and nutrition guidance, among others.

Overall, HIMS ranks 3rd on our list of Tuesday’s best-performing stocks. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than HIMS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.